Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $195

Revolution Medicines

Revolution Medicines

RVMD

0.00

Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ: RVMD) with a Outperform and raises the price target from $165 to $195.